

09/043,358

-2-

PD-5454-01-EMA

Mellick et al., Arch. Phys. Med. Rehabil., Vol. 78, 1997, was published after the priority date of the instant invention therefore it is not available as a grounds of rejection of Claims 1-15 under 35 U.S.C. 103(a).

Mellick et al., Letters, Vol. 10, No. 4, May 1995, is a discussion of the use of gabapentin (Neurontin) for the treatment of reflex sympathetic dystrophy (RSD). The structure of the compound of the reference is found in the attached USP Dictionary, see the second column halfway down where gabapentin is shown to have a cyclohexyl ring. In contrast the instant claims is a straight chain compound. There is no teaching or suggestion in the reference to use anything but gabapentin. The reference is not a proper grounds for rejection under 35 U.S.C. 103(a) and Applicant urges its removal.

In view of the above remarks Applicant deems the rejection of Claims 1-15 under 35 U.S.C. 103 overcome and ask the Examiner to pass the case to issue.

Respectfully submitted,

Elizabeth M. Anderson

Elizabeth M. Anderson
Reg. No. 31,585
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7304
Fax (734) 622-1553

Attachment – USP Dictionary (2 pages)

EA1P4891.doc


BEST AVAILABLE COPY

USP Dictionary


of
USAN
and
International
Drug
Names



Furterene. $C_{10}H_9N_7O$. 243.23. 2,4,7-Triamino-6-(2-furyl)pteridine. CAS-7761-75-3. INN; DCF; MI.



Furtrithonium Iodide. $C_8H_{14}INO$. 267.11. Furfuryl(trimethylammonium) iodide. CAS-541-64-0; CAS-7618-86-2 [furtrithonium]. INN; MI. Furmethide Iodide (SmithKline Beecham†)




Furtrimethonium Iodide — See Furtrithonium Iodide.

Fusafungine. Antibiotic obtained from cultures of a *fusarium* belonging to *Lateritium* Wt. section, or the same substance produced by any other means. CAS-1393-87-9. INN; BAN; DCF; MI. \diamond S 314


Fusidate Sodium [1968] (fyoo' si date). $C_{31}H_{47}NaO_8$. 506.71. [Sodium Fusidate is JAN.] (1) 29-Nordammar-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, monosodium salt, (3 α ,4 α ,8 α ,9 β ,11 α ,13 α ,14 β ,16 β ,17Z)-; (2) Sodium 3 α ,11 α ,16 β -trihydroxy-29-nor-8 α ,9 β ,13 α ,14 β -dammar-17(20),24-dien-21-oate 16-acetate; (3) Fusidic acid, sodium salt. CAS-751-94-0; CAS-6990-06-3 [fusidic acid]. Antibacterial. Fucidine (Bristol-Myers Squibb†) \diamond SQ 16360

Fusidic Acid [1967] (fyoo si' dik). $C_{31}H_{48}O_8$. 516.72. (1) 29-Nordammar-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3 α ,4 α ,8 α ,9 β ,11 α ,13 α ,14 β ,16 β ,17Z)-; (2) 3 α ,11 α ,16 β -Trihydroxy-29-nor-8 α ,9 β ,13 α ,14 β -dammar-17(20),24-dien-21-oic acid 16-acetate; (3) Fusidic acid. CAS-6990-06-3. INN; BAN. Antibacterial. (Bristol-Myers Squibb†) \diamond SQ 16,603



FUT-175. Code designation for Nafamostat Mesylate.

Fazlocillin. $C_{25}H_{26}N_6O_8S$. 570.59. (2S,5R,6R)-6-[(2R)-2-[3-[(E)-Furfurylideneamino]-2-oxo-1-imidazolidinyl]carboxamido]-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. CAS-66327-51-3. INN; BAN. \diamond BAY YK 4999



FW Toric. Bausch & Lomb brand of Lidofilcon A.

FWH 399. Code designation for Troxonium Tosilate.

† Brand name formerly used, and/or firm no longer concerned with this product.

Fytic Acid (INN) — See Phytic Acid.

2-G. Marion Merrell Dow† brand of Guaifenesin.

G-4. Code designation for Dichlorophen.

G6M — See Galamustine.

G-101, SCY-Er. Code designation for Erythromycin Salmacedin.

G-201, SCY. Code designation for Salmacedin.

G-24480. Code designation for Dimpylate.

G-25178. Code designation for Prodeconium Bromide.

G-25766. Code designation for Clorindione.

G 26,872. Code designation for Phenbutazone Sodium Glycerate.

G 30320. Code designation for Clofazimine.

G-32883. Code designation for Carbamazepine.

G-33040. Code designation for Opipramol Hydrochloride.

G-33182. Code designation for Chlorthalidone.

G 34586. Code designation for Clomipramine Hydrochloride.


G-35020. Code designation for Desipramine Hydrochloride.

G 35259. Code designation for Ketipramine Fumarate.


G-704,650. Code designation for Alendronate Sodium.

^{67}Ga — See Gallium Citrate Ga 67.

Gabapentin [1989] (ga' ba pen tin). $C_9H_{17}NO_2$. 171.24. (1) Cyclohexanecarboxylic acid, 1-(aminomethyl)-; (2) 1-(Aminomethyl)cyclohexanecarboxylic acid. CAS-60142-96-3. INN; BAN. Anticonvulsant. Neurontin (Parke-Davis) \diamond CI-945; GOE 3450




Gabexate. $C_{16}H_{23}N_7O_4$. 321.38. [Gabexate Mesilate is JAN.] Ethyl p-hydroxybenzoate 6-guanidinoheptanoate. CAS-39492-01-8. INN; MI.




Gabitril. Abbott brand of Tiagabine Hydrochloride.

Gaboxadol. $C_6H_8N_2O_2$. 140.14. 4,5,6,7-Tetrahydroisoxazole[5,4-c]pyridin-3-ol. CAS-64603-91-4. INN.



Gabren. Synthelabo Pharmacie, France, brand of Progabide.

Gacyclidine. $C_{16}H_{25}NS$. 263.45. 1-[cis-2-Methyl-1-(2-thienyl)cyclohexyl]piperidine. CAS-68134-81-6. INN.



FAX RECEIVED

**WARNER
LAMBERT**

Corporate Legal Division

APR 16 1999

GROUP 1600

2800 Plymouth Road
Ann Arbor, MI 48105
FAX: (734) 622 - 1553

OFFICIAL

To: Examiner J. Reamer Group 1614	Re: USSN 09/043,358
Fax: 703-308-7924 or 4556	Date: April 16, 1999
From: Elizabeth M. Anderson	Pages Sent: 6
If this fax is not received clearly, call (734) 622 - 7615	

NOTICE: This facsimile is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure. If the reader of this facsimile is not the intended recipient, or an employee or agent responsible for delivering the facsimile to the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of the communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately at the telephone number(s) listed above and return the original facsimile to us at the above address by U.S. mail, the cost of which will be reimbursed. Thank you.

Revised: 26 August 1993

Message:

RE: USSN 09/043,358
Our Reference; Docket 5454-01-EMA

AMENDMENT follows.

APR 16 1999

GROUP 1600

OFFICIAL

Certification Under 37 C.F.R. § 1.8 or 1.10

I hereby certify that this correspondence and any attachments are, on the date below, being:

- ☐ deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
- ☒ facsimile transmitted to the Patent and Trademark Office, facsimile number 703-308-7924 or 459

Date: April 16, 1999

Signature

Cindy Malocha

Cindy Malocha

Typed/Printed Name of Person Making Certification

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): LAKHBIR SINGH

Examiner: J. REAMER

Application No.: 09/043,358

Art Unit: 1614

Filed: JULY 15, 1998

Title: ISOBUTYLGABA AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN

Assistant Commissioner for Patents
Washington, D.C. 20231

Transmittal of an Amendment and/or Reply Under 37 C.F.R. § 1.111 or 1.115

Assistant Commissioner for Patents:

Transmitted herewith is an amendment and/or reply relating to the above-identified patent application.

☒ No fee is required for the amended claims.☐ A Petition for an Extension of Time is attached.

Authorization is hereby given to charge any fee to Deposit Account No. 23-0455, and the Commissioner is hereby authorized to charge any greater amount as may be required or credit any overpayment to Deposit Account No. 23-0455.

Respectfully submitted,

April 16, 1999
DateElizabeth M. Anderson
Elizabeth M. Anderson
Registration No. 31,585
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7304
Fax (734) 622-1553

Attachments

- ☒ Reply/Amendment
- ☐ Two additional copies of this paper
- ☐ Petition for Extension of Time
- ☐ Return postcard

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.